missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human FSD1 (aa 252-341) Control Fragment Recombinant Protein
Click to view available options
Quantité:
100 μl
Conditionnement:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (93%), Rat (93%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-60255 (PA5-60255. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
FSD1 encodes a centrosome associated protein that is characterized by an N-terminal coiled-coil region downstream of B-box (BBC) domain, a central fibronectin type III domain, and a C-terminal repeats in splA and RyR (SPRY) domain. The encoded protein associates with a subset of microtubules and may be involved in the stability and organization of microtubules during cytokinesis.
Spécification
Spécification
| Numéro d’adhésion | Q9BTV5 |
| Concentration | ≥5.0 mg/mL |
| À utiliser avec (application) | Blocking Assay, Control |
| Formule | 1 M urea, PBS with no preservative; pH 7.4 |
| Identification génétique (Entrez) | 79187 |
| Nom | Human FSD1 (aa 252-341) Control Fragment |
| Quantité | 100 μl |
| État réglementaire | RUO |
| Alias de gène | fibronectin type 3 and SPRY (spla, ryanodine) domain containing (with coiled-coil motif) 1; fibronectin type 3 and SPRY domain containing 1; fibronectin type 3 and SPRY domain-containing protein; fibronectin type III and SPRY domain containing 1; fibronectin type III and SPRY domain-containing protein 1; Fsd1; GLFND; Microtubule-associated protein GLFND; MID1-related protein 1; midline 1-related protein 1; MIR1; VLP27 |
| Nom usuel | FSD1 |
| Afficher plus |
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu